APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatic Encephalopathy Drug Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatic Encephalopathy Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatic Encephalopathy Drug market include Umecrine Cognition AB, Spherium Biomed S.L., Rebiotix Inc., Ocera Therapeutics, Inc., KannaLife Sciences, Inc., Horizon Pharma Plc, Cosmo Pharmaceuticals S.p.A and Alfa Wassermann S.p.A, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatic Encephalopathy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatic Encephalopathy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatic Encephalopathy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatic Encephalopathy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatic Encephalopathy Drug Segment by Company

Umecrine Cognition AB

Spherium Biomed S.L.

Rebiotix Inc.

Ocera Therapeutics, Inc.

KannaLife Sciences, Inc.

Horizon Pharma Plc

Cosmo Pharmaceuticals S.p.A

Alfa Wassermann S.p.A

Hepatic Encephalopathy Drug Segment by Type

GR-3027

KLS-13019

RBX-2660

SYNB-1020

Others

Hepatic Encephalopathy Drug Segment by Application

Clinic

Hospital

Others

Hepatic Encephalopathy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hepatic Encephalopathy Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatic Encephalopathy Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatic Encephalopathy Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatic Encephalopathy Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatic Encephalopathy Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatic Encephalopathy Drug industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatic Encephalopathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatic Encephalopathy Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatic Encephalopathy Drug Industry Trends Table 2. Hepatic Encephalopathy Drug Industry Drivers Table 3. Hepatic Encephalopathy Drug Industry Opportunities and Challenges Table 4. Hepatic Encephalopathy Drug Industry Restraints Table 5. Global Hepatic Encephalopathy Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatic Encephalopathy Drug Revenue Share by Company (2021-2026) Table 7. Global Hepatic Encephalopathy Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Hepatic Encephalopathy Drug Sales Volume Share by Company (2021-2026) Table 9. Global Hepatic Encephalopathy Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hepatic Encephalopathy Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatic Encephalopathy Drug Key Company Manufacturing Base & Headquarters Table 12. Global Hepatic Encephalopathy Drug Company, Product Type & Application Table 13. Global Hepatic Encephalopathy Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatic Encephalopathy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of GR-3027 Table 18. Significant Companies of KLS-13019 Table 19. Significant Companies of RBX-2660 Table 20. Significant Companies of SYNB-1020 Table 21. Significant Companies of Others Table 22. Global Hepatic Encephalopathy Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Hepatic Encephalopathy Drug Sales Volume by Type (2021-2026) & (W Units) Table 24. Global Hepatic Encephalopathy Drug Sales Volume by Type (2027-2032) & (W Units) Table 25. Global Hepatic Encephalopathy Drug Sales Volume Share by Type (2021-2026) Table 26. Global Hepatic Encephalopathy Drug Sales Volume Share by Type (2027-2032) Table 27. Global Hepatic Encephalopathy Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hepatic Encephalopathy Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Hepatic Encephalopathy Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Hepatic Encephalopathy Drug Sales Value Share by Type (2021-2026) Table 31. Global Hepatic Encephalopathy Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Others Table 35. Global Hepatic Encephalopathy Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Hepatic Encephalopathy Drug Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Hepatic Encephalopathy Drug Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Hepatic Encephalopathy Drug Sales Volume Share by Application (2021-2026) Table 39. Global Hepatic Encephalopathy Drug Sales Volume Share by Application (2027-2032) Table 40. Global Hepatic Encephalopathy Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Hepatic Encephalopathy Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Hepatic Encephalopathy Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Hepatic Encephalopathy Drug Sales Value Share by Application (2021-2026) Table 44. Global Hepatic Encephalopathy Drug Sales Value Share by Application (2027-2032) Table 45. Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Hepatic Encephalopathy Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2021-2026) Table 48. Global Hepatic Encephalopathy Drug Sales by Region (2027-2032) & (W Units) Table 49. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2027-2032) Table 50. Global Hepatic Encephalopathy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Hepatic Encephalopathy Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Hepatic Encephalopathy Drug Sales Value Share by Region (2021-2026) Table 53. Global Hepatic Encephalopathy Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Hepatic Encephalopathy Drug Sales Value Share by Region (2027-2032) Table 55. Global Hepatic Encephalopathy Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Hepatic Encephalopathy Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Hepatic Encephalopathy Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 60. Global Hepatic Encephalopathy Drug Sales Market Share by Country (2021-2026) Table 61. Global Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 62. Global Hepatic Encephalopathy Drug Sales Market Share by Country (2027-2032) Table 63. Global Hepatic Encephalopathy Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Hepatic Encephalopathy Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Hepatic Encephalopathy Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Hepatic Encephalopathy Drug Sales Value Market Share by Country (2027-2032) Table 67. Umecrine Cognition AB Company Information Table 68. Umecrine Cognition AB Business Overview Table 69. Umecrine Cognition AB Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio Table 71. Umecrine Cognition AB Recent Development Table 72. Spherium Biomed S.L. Company Information Table 73. Spherium Biomed S.L. Business Overview Table 74. Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio Table 76. Spherium Biomed S.L. Recent Development Table 77. Rebiotix Inc. Company Information Table 78. Rebiotix Inc. Business Overview Table 79. Rebiotix Inc. Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio Table 81. Rebiotix Inc. Recent Development Table 82. Ocera Therapeutics, Inc. Company Information Table 83. Ocera Therapeutics, Inc. Business Overview Table 84. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 86. Ocera Therapeutics, Inc. Recent Development Table 87. KannaLife Sciences, Inc. Company Information Table 88. KannaLife Sciences, Inc. Business Overview Table 89. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 91. KannaLife Sciences, Inc. Recent Development Table 92. Horizon Pharma Plc Company Information Table 93. Horizon Pharma Plc Business Overview Table 94. Horizon Pharma Plc Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio Table 96. Horizon Pharma Plc Recent Development Table 97. Cosmo Pharmaceuticals S.p.A Company Information Table 98. Cosmo Pharmaceuticals S.p.A Business Overview Table 99. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 101. Cosmo Pharmaceuticals S.p.A Recent Development Table 102. Alfa Wassermann S.p.A Company Information Table 103. Alfa Wassermann S.p.A Business Overview Table 104. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 106. Alfa Wassermann S.p.A Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Hepatic Encephalopathy Drug Distributors List Table 110. Hepatic Encephalopathy Drug Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drug Product Image Figure 2. Global Hepatic Encephalopathy Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy Drug Sales (2021-2032) & (W Units) Figure 5. Global Hepatic Encephalopathy Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hepatic Encephalopathy Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. GR-3027 Image Figure 10. KLS-13019 Image Figure 11. RBX-2660 Image Figure 12. SYNB-1020 Image Figure 13. Others Image Figure 14. Global Hepatic Encephalopathy Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Hepatic Encephalopathy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatic Encephalopathy Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Hepatic Encephalopathy Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hepatic Encephalopathy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Hepatic Encephalopathy Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Hepatic Encephalopathy Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Hepatic Encephalopathy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Hepatic Encephalopathy Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Hepatic Encephalopathy Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Hepatic Encephalopathy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Hepatic Encephalopathy Drug Sales Value Share by Application (2021-2032) Figure 29. Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Hepatic Encephalopathy Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Hepatic Encephalopathy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Hepatic Encephalopathy Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Hepatic Encephalopathy Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Hepatic Encephalopathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Hepatic Encephalopathy Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Hepatic Encephalopathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Hepatic Encephalopathy Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Hepatic Encephalopathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Hepatic Encephalopathy Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Hepatic Encephalopathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Hepatic Encephalopathy Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Hepatic Encephalopathy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Hepatic Encephalopathy Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Hepatic Encephalopathy Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • GR-3027
  • KLS-13019
  • RBX-2660
  • SYNB-1020
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Umecrine Cognition AB
  • Spherium Biomed S.L.
  • Rebiotix Inc.
  • Ocera Therapeutics, Inc.
  • KannaLife Sciences, Inc.
  • Horizon Pharma Plc
  • Cosmo Pharmaceuticals S.p.A
  • Alfa Wassermann S.p.A

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatic Encephalopathy Drug Sales Value (2021-2032)
  4. 1.2.2 Global Hepatic Encephalopathy Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatic Encephalopathy Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatic Encephalopathy Drug Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drug Industry Trends
  2. 2.2 Hepatic Encephalopathy Drug Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drug Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drug Industry Restraints
3 Hepatic Encephalopathy Drug Market by Company
  1. 3.1 Global Hepatic Encephalopathy Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hepatic Encephalopathy Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hepatic Encephalopathy Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatic Encephalopathy Drug Average Price by Company (2021-2026)
  5. 3.5 Global Hepatic Encephalopathy Drug Company Ranking (2024-2026)
  6. 3.6 Global Hepatic Encephalopathy Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatic Encephalopathy Drug Company Product Type and Application
  8. 3.8 Global Hepatic Encephalopathy Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatic Encephalopathy Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatic Encephalopathy Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatic Encephalopathy Drug Market by Type
  1. 4.1 Hepatic Encephalopathy Drug Type Introduction
  2. 4.1.1 GR-3027
  3. 4.1.2 KLS-13019
  4. 4.1.3 RBX-2660
  5. 4.1.4 SYNB-1020
  6. 4.1.5 Others
  7. 4.2 Global Hepatic Encephalopathy Drug Sales Volume by Type
  8. 4.2.1 Global Hepatic Encephalopathy Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hepatic Encephalopathy Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Hepatic Encephalopathy Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Hepatic Encephalopathy Drug Sales Value by Type
  12. 4.3.1 Global Hepatic Encephalopathy Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Hepatic Encephalopathy Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Hepatic Encephalopathy Drug Sales Value Share by Type (2021-2032)
5 Hepatic Encephalopathy Drug Market by Application
  1. 5.1 Hepatic Encephalopathy Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Hepatic Encephalopathy Drug Sales Volume by Application
  6. 5.2.1 Global Hepatic Encephalopathy Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hepatic Encephalopathy Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hepatic Encephalopathy Drug Sales Value by Application
  10. 5.3.1 Global Hepatic Encephalopathy Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatic Encephalopathy Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hepatic Encephalopathy Drug Sales Value Share by Application (2021-2032)
6 Hepatic Encephalopathy Drug Regional Sales and Value Analysis
  1. 6.1 Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatic Encephalopathy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatic Encephalopathy Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatic Encephalopathy Drug Sales by Region (2027-2032)
  5. 6.3 Global Hepatic Encephalopathy Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatic Encephalopathy Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatic Encephalopathy Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatic Encephalopathy Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatic Encephalopathy Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatic Encephalopathy Drug Sales Value (2021-2032)
  12. 6.6.2 North America Hepatic Encephalopathy Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatic Encephalopathy Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatic Encephalopathy Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatic Encephalopathy Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatic Encephalopathy Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatic Encephalopathy Drug Sales Value (2021-2032)
  21. 6.9.2 South America Hepatic Encephalopathy Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatic Encephalopathy Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatic Encephalopathy Drug Sales Value Share by Country, 2025 VS 2032
7 Hepatic Encephalopathy Drug Country-level Sales and Value Analysis
  1. 7.1 Global Hepatic Encephalopathy Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatic Encephalopathy Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatic Encephalopathy Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatic Encephalopathy Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatic Encephalopathy Drug Sales by Country (2027-2032)
  6. 7.4 Global Hepatic Encephalopathy Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatic Encephalopathy Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatic Encephalopathy Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatic Encephalopathy Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatic Encephalopathy Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatic Encephalopathy Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Umecrine Cognition AB
  2. 8.1.1 Umecrine Cognition AB Company Information
  3. 8.1.2 Umecrine Cognition AB Business Overview
  4. 8.1.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio
  6. 8.1.5 Umecrine Cognition AB Recent Developments
  7. 8.2 Spherium Biomed S.L.
  8. 8.2.1 Spherium Biomed S.L. Company Information
  9. 8.2.2 Spherium Biomed S.L. Business Overview
  10. 8.2.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio
  12. 8.2.5 Spherium Biomed S.L. Recent Developments
  13. 8.3 Rebiotix Inc.
  14. 8.3.1 Rebiotix Inc. Company Information
  15. 8.3.2 Rebiotix Inc. Business Overview
  16. 8.3.3 Rebiotix Inc. Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio
  18. 8.3.5 Rebiotix Inc. Recent Developments
  19. 8.4 Ocera Therapeutics, Inc.
  20. 8.4.1 Ocera Therapeutics, Inc. Company Information
  21. 8.4.2 Ocera Therapeutics, Inc. Business Overview
  22. 8.4.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio
  24. 8.4.5 Ocera Therapeutics, Inc. Recent Developments
  25. 8.5 KannaLife Sciences, Inc.
  26. 8.5.1 KannaLife Sciences, Inc. Company Information
  27. 8.5.2 KannaLife Sciences, Inc. Business Overview
  28. 8.5.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio
  30. 8.5.5 KannaLife Sciences, Inc. Recent Developments
  31. 8.6 Horizon Pharma Plc
  32. 8.6.1 Horizon Pharma Plc Company Information
  33. 8.6.2 Horizon Pharma Plc Business Overview
  34. 8.6.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio
  36. 8.6.5 Horizon Pharma Plc Recent Developments
  37. 8.7 Cosmo Pharmaceuticals S.p.A
  38. 8.7.1 Cosmo Pharmaceuticals S.p.A Company Information
  39. 8.7.2 Cosmo Pharmaceuticals S.p.A Business Overview
  40. 8.7.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio
  42. 8.7.5 Cosmo Pharmaceuticals S.p.A Recent Developments
  43. 8.8 Alfa Wassermann S.p.A
  44. 8.8.1 Alfa Wassermann S.p.A Company Information
  45. 8.8.2 Alfa Wassermann S.p.A Business Overview
  46. 8.8.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio
  48. 8.8.5 Alfa Wassermann S.p.A Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatic Encephalopathy Drug Value Chain Analysis
  2. 9.1.1 Hepatic Encephalopathy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatic Encephalopathy Drug Sales Mode & Process
  6. 9.2 Hepatic Encephalopathy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatic Encephalopathy Drug Distributors
  9. 9.2.3 Hepatic Encephalopathy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst